Search for: "Boehringer Ingelheim Pharmaceutical, Inc" Results 61 - 80 of 86
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Oct 2012, 12:53 pm by Joe Consumer
s announcement of another big health care fraud settlement, specifically, Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted.… Thursday's announcement is the latest in a series of settlements with pharmaceutical companies engaging in so-called off-label marketing. [read post]
26 Apr 2007, 9:28 am
The two big trade mark decisions of the European Court of Justice today have been a little overshadowed by the festivities for World Intellectual Property Day, but the IPKat took just enough time off from his ecstatic celebrations to check the Curia website and see what the ECJ had in store for him.Right: objection to the repackaging of pharma products has led to some grey goods traders taking extreme measures to avoid trade mark infringment litigationCase C-348/04, Boehringer… [read post]
1 Aug 2019, 8:30 am by Seeger Weiss LLP
Boehringer Ingelheim Corp., et al., a $150 million settlement with GlaxoSmithKline PLC, and a $190 million settlement with Aventis Pharmaceuticals, Inc. [read post]
6 Nov 2007, 5:55 am
Rosenbaum, District of MinnesotaNature of Suits: Consists of 58 actions against Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. arising from use of Mirapex, a treatment for Parkinson's disease, which alleged causes obsessive pleasure- and reward-seeking behavior, such as gambling.In re Kugel Mesh Hernia Patch Products Liability Litigation, MDL 1842Filed 2/28/07 and ordered to be transferred on 6/22/2007Transferee Judge and Court: Mary H. [read post]
15 Jun 2012, 2:51 pm by bradhendrickslawfirm
Pradaxa Approved by FDA in 2010 and Investigated by 2011 In 2010, the United States Food & Drug Administration (FDA) approved Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., as a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. [read post]
12 Jan 2012, 4:21 am
The IPKat has always been unhappy at the bit in Case C-348/04 Boehringer Ingelheim KG v Swingward Ltd: where the Court of Justice of the European Union said: "Where a parallel importer has failed to give prior notice to the trade mark proprietor concerning a repackaged pharmaceutical product, he infringes that proprietor’s rights on the occasion of any subsequent importation of that product, so long as he has not given the proprietor such notice. [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
9 Nov 2012, 2:15 pm by Tom Lamb
November 7, 2012:  "Interim Results from RELY-ABLE®, the RE-LY® Extension Study, Provide Additional Clinical Evidence for the Safety of Pradaxa® (dabigatran etexilate mesylate)"  (Drug company Press Release) @EXCERPT:  Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim results from the RELY-ABLE® trial, a long-term extension of the RE-LY® study. [read post]
8 Jul 2015, 8:31 am by Katharyn Grant (US)
Labs., Inc., 625 F.2d 1055 (3d Cir. 1980) (holding unique coloring of prescription drug capsule constituted protectable trade dress); Boehringer Ingelheim G.m.b.H. v. [read post]
5 Jun 2014, 7:06 am by Daniel Schwartz
 Boehringer Ingelheim Pharmaceuticals, Inc., which was decided just a few months before I started my career in employment law. [read post]
28 Jul 2013, 9:29 am by Spencer Aronfeld
  Some of the other diabetes drugs being investigated include Bydureon and Onglyza, sold by Bristol-Myers Squibb; AstraZeneca and Victoza from Novo Nordisk; Tradjenta from Eli Lilly and Boehringer Ingelheim; and Nesina from Takeda. [read post]
17 Oct 2007, 8:59 am
  And now the tipping point is in sight as more law departments and law firms inch towards greater use of evaluations and assessments-- and trumpet the benefits.General Counsel Scott Terrillion, of Boehringer Ingelheim Pharmaceuticals Inc, uses an "evaluative selection method" to find the best attorneys for his company, with diversity being a natural consequence. [read post]
31 Jan 2011, 8:10 am by Stefanie Levine
Terminal Disclaimers and Section 121 Boehringer Ingelheim International GmbH v. [read post]
2 Nov 2012, 11:58 am by Bexis
Boehringer Ingelheim Pharmaceuticals, Inc., 2009 WL 702007, at *3-4 (D. [read post]